Search
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744] … [L40739] Patient T-cells are reprogrammed with a transgene encoding a specific chimeric antigen receptor (CAR) which features two BCMA-targeting single-domain antibodies.
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[L40298] In September 2022, Skysona was approved by the FDA.[L43247]
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalIt is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. … Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class.
Categories: Angiotensin 2 Receptor Blocker, Angiotensin Receptor AntagonistsEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Categories: Sphingosine-1-phosphate (S1P) receptor modulatorsGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalPacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,
Loprazolam
go.drugbank.com/drugs/DB13643ExperimentalIt is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. It is not an FDA-approved drug.